V 3526

Drug Profile

V 3526

Alternative Names: V3526; VEE 3526; VEE IA/B V3526; VEE Vaccine; Venezuelan equine encephalitis virus vaccine - DynPort

Latest Information Update: 16 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator United States Army Medical Research Institute of Infectious Diseases; University of North Carolina at Chapel Hill
  • Developer Charles River Laboratories; DynPort Vaccine Company
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Encephalitis virus infections

Most Recent Events

  • 09 Feb 2017 Preclinical development is ongoing in USA (NCT03051386)
  • 09 Feb 2017 US Army Medical Research and Materiel Command plans a phase II trial for Encephalomyelitis (Prevention) (In Volunteers) in USA (NCT03051386)
  • 31 Oct 2006 Northwest Kinetics has been acquired by Charles River Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top